PT - JOURNAL ARTICLE AU - Dauchet, Luc AU - Lambert, Marc AU - Gauthier, Victoria AU - Poissy, Julien AU - Faure, Karine AU - Facon, Alain AU - Yelnik, Cécile AU - Panaget, Sophie AU - Plagnieux, Thierry AU - Verfaillie, Florent AU - Mathieu, Daniel AU - Goldstein, Patrick AU - Meirhaeghe, Aline AU - Amouyel, Philippe AU - , TI - ACE inhibitors, AT1 receptor blockers and COVID-19: clinical epidemiology evidences for a continuation of treatments. The ACER-COVID study AID - 10.1101/2020.04.28.20078071 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.28.20078071 4099 - http://medrxiv.org/content/early/2020/05/01/2020.04.28.20078071.short 4100 - http://medrxiv.org/content/early/2020/05/01/2020.04.28.20078071.full AB - Aims The question of interactions between the renin angiotensin aldosterone system drugs and the incidence and prognosis of COVID-19 infection has been raised by the medical community. We hypothesised that if patients treated with ACE inhibitors (ACEI) or AT1 receptor blockers (ARB) were more prone to SARS-CoV2 infection and had a worse prognosis than untreated patients, the prevalence of consumption of these drugs would be higher in patients with COVID-19 compared to the general population.Methods and results We used a clinical epidemiology approach based on the estimation of standardised prevalence ratio (SPR) of consumption of ACEI and ARB in four groups of patients (including 187 COVID-19 positive) with increasing severity referred to the University hospital of Lille and in three French reference samples (the exhaustive North population (n=1,569,968), a representative sample of the French population (n=414,046), a random sample of Lille area (n=1,584)).The SPRs of ACEI and ARB did not differ as the severity of the COVID-19 patients increased, being similar to the regular consumption of these drugs in the North of France population with the same non-significant increase for both treatment (1.17 [0.83–1.67]). A statistically significant increase in the SPR of ARB (1.56 [1.02–2.39]) was observed in intensive care unit patients only. After stratification on obesity, this increase was limited to the high risk subgroup of obese patients.Conclusions Our results strongly support the recommendation that ACEI and ARB should be continued in the population and in COVID-19 positive patients, reinforcing the position of several scientific societies.Competing Interest StatementNone declared. Philippe AMOUYEL reports, outside the submitted work, personal fees from Fondation Alzheimer and personal fees and other from Genoscreen.Funding StatementThis work was supported by the Centre Hospitalier Universitaire de Lille (CHU Lille), the Lille University, the Institut National de la Santé et de la Recherche Médicale (Inserm) and the Institut Pasteur de Lille.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data can be obtained by contacting the corresponding author